BACKGROUND: Late graft failure (LGF) is believed to be the consequence of immunologic and nonimmunologic insults leading to progressive deterioration in kidney function. We studied recipients with new onset late kidney graft dysfunction (n=173) to determine the importance of C4d staining and circulating donor-specific antibody (DSA) in subsequent LGF. METHODS: One hundred seventy-three subjects transplanted before October 1, 2005 (mean time after transplant 7.3+/-6.0 years) had a baseline serum creatinine level of 1.4+/-0.3 mg/dL before January 1, 2006 and underwent biopsy for new onset graft dysfunction after that date (mean creatinine at biopsy 2.7+/-1.6 mg/dL). Statistical analysis was based on central DSA and blinded pathology determinations. RESULTS: Subjects were divided into four groups based on C4d and DSA: no C4d, no DSA (group A; n=74); only DSA (group B; n=31); only C4d (group C; n=28); and both C4d and DSA (group D; n=40). Among DSA+ recipients (groups B and D), group D had broader reactivity and a stronger DSA response. After 2 years, groups C and D (C4d+) were at significantly greater risk for LGF than groups A and B. Adjusting for inflammation (Banff i, t, g, and ptc scores) did not change the outcome. Local diagnosis of calcineurin inhibitor nephrotoxicity was spread across all four subgroups and did not impact risk of LGF. CONCLUSIONS: Evidence of antibody-mediated injury (DSA or C4d) is common (57%) in patients with new onset late kidney allograft dysfunction. The risk of subsequent graft failure is significantly worse in the presence of C4d+ staining.
BACKGROUND: Late graft failure (LGF) is believed to be the consequence of immunologic and nonimmunologic insults leading to progressive deterioration in kidney function. We studied recipients with new onset late kidney graft dysfunction (n=173) to determine the importance of C4d staining and circulating donor-specific antibody (DSA) in subsequent LGF. METHODS: One hundred seventy-three subjects transplanted before October 1, 2005 (mean time after transplant 7.3+/-6.0 years) had a baseline serum creatinine level of 1.4+/-0.3 mg/dL before January 1, 2006 and underwent biopsy for new onset graft dysfunction after that date (mean creatinine at biopsy 2.7+/-1.6 mg/dL). Statistical analysis was based on central DSA and blinded pathology determinations. RESULTS: Subjects were divided into four groups based on C4d and DSA: no C4d, no DSA (group A; n=74); only DSA (group B; n=31); only C4d (group C; n=28); and both C4d and DSA (group D; n=40). Among DSA+ recipients (groups B and D), group D had broader reactivity and a stronger DSA response. After 2 years, groups C and D (C4d+) were at significantly greater risk for LGF than groups A and B. Adjusting for inflammation (Banff i, t, g, and ptc scores) did not change the outcome. Local diagnosis of calcineurin inhibitor nephrotoxicity was spread across all four subgroups and did not impact risk of LGF. CONCLUSIONS: Evidence of antibody-mediated injury (DSA or C4d) is common (57%) in patients with new onset late kidney allograft dysfunction. The risk of subsequent graft failure is significantly worse in the presence of C4d+ staining.
Authors: Markus Wahrmann; Bernd Döhler; Andrea Ruhenstroth; Helmuth Haslacher; Thomas Perkmann; Markus Exner; Andrew J Rees; Georg A Böhmig Journal: J Am Soc Nephrol Date: 2010-12-16 Impact factor: 10.121
Authors: M Mengel; B Sis; M Haas; R B Colvin; P F Halloran; L C Racusen; K Solez; L Cendales; A J Demetris; C B Drachenberg; C F Farver; E R Rodriguez; W D Wallace; D Glotz Journal: Am J Transplant Date: 2012-02-02 Impact factor: 8.086
Authors: Arthur J Matas; Ann Fieberg; Roslyn B Mannon; Robert Leduc; Joe Grande; Bertram L Kasiske; Michael Cecka; Robert Gaston; Lawrence Hunsicker; John Connett; Fernando Cosio; Sita Gourishankar; David Rush Journal: Am J Transplant Date: 2019-01-24 Impact factor: 8.086
Authors: K de Leur; M C Clahsen-van Groningen; T P P van den Bosch; G N de Graav; D A Hesselink; J N Samsom; C C Baan; K Boer Journal: Clin Exp Immunol Date: 2018-02-02 Impact factor: 4.330
Authors: Arjang Djamali; Nancy A Wilson; Elizabeth A Sadowski; Wei Zha; David Niles; Omeed Hafez; Justin R Dorn; Thomas R Mehner; Paul C Grimm; F Michael Hoffmann; Weixiong Zhong; Sean B Fain; Shannon R Reese Journal: Transplantation Date: 2016-06 Impact factor: 4.939
Authors: Chaitali Passey; Angela K Birnbaum; Richard C Brundage; David P Schladt; William S Oetting; Robert E Leduc; Ajay K Israni; Weihua Guan; Arthur J Matas; Pamala A Jacobson Journal: Pharmacogenomics Date: 2012-07 Impact factor: 2.533